NL-OMON32125已完成2 期
A Randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors. - CA182-026
Bristol-Myers Squibb0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Histologic or cytologic confirmed diagnosis of a solid tumor (non-small cell lung, gastric/esophageal adenocarcinoma, soft tissue sarcoma, transitional cell carcinoma and pancreatic cancer including ampulla of Vater tumors) which has progressed on standard therapy or for whom no standard therapy is known.
- •Measurable disease
- •Men and women, age 18 or older
- •Life expectancy at least 3 months
- •ECOG performance status 0 or 1 (generally fit and mobile)
- •Adequate tumor sample for FGF-2 assay
- •Adequate bone marrow, renal and hepatic function
- •Adequate recovery from recent surgery and radiation therapy - one week for minor surgery and 8 weeks for major surgery or radiation therapy.
- •At least 3 weeks must have relapsed since last dose of chemotherapy or targeted agents providing the subject has recovered from all toxicities. At least 8 weeks must have elapsed from the last dose of bevacizumab, prior to beginning protocol therapy.
排除标准
- •Women of child bearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy during study and up to 12 weeks after the last dose of drug, are pregnant or breastfeeding or have a positive pregnancy test on enrollment or prior to investigational product administration.
- •Sexually active fertile men not using effective birth control if their partners are WOCBP, including up to 12 weeks after the last dose of investigational product.
- •Actual diagnosis of brain metastasis or any known signs and symptoms, unless confirmed negative by means of a CT scan.
- •Centrally cavitating lung lesions.
- •History of thrombo-embolic disease within the last six months requiring therapy.
- •Other primary malignancy except carcinoma in situ of cervix or urinary bladder or non-melanoma skin cancer.
- •History of poor wound healing or non healing ulcers
- •Uncontrolled or significant cardiovascular disease including myocardial infarction within 12 months, uncontrolled angina within 12 months; congestive heart failure (Class III-IV New York Heart Association (NYHA) and valvular heart disease grade 2.
- •Uncontrolled hypertension even despite appropriate treatment.
- •History of stroke, transient ischemic attack or other ischemic event.
- •Mental incapacitation or psychiatric illness which would preclude study participation.
- •Inability to swallow tablets or untreated malabsorption syndrome.
- •History of allergy to brivanib its drug class or related compounds.
- •Exposure to any investigational drug within 4 weeks of enrollment
- •Other concurrent chemotherapy, hormonal therapy, immunotherapy regimens or radiotherapy, standard or investigational. Subjects may continue to receive hormone replacement therapy.
- •Prior exposure to brivanib.
研究者
相似试验
进行中（未招募）
1 期
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor TypesEUCTR2008-000087-16-GBBristol-Myers Squibb International Corporation400
进行中（未招募）
1 期
A randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors.Revised protocol 02 incorporating Amendment 02 & 03 & Administrative Letter 01+ Pharmacogenetics Blood Sample Amendment 01 (version 1.0, dated 28-Jan-2008)Subjects with Advanced Solid TumorsMedDRA version: 9.1Level: LLTClassification code 10065252Term: Solid tumorEUCTR2008-000087-16-DEBristol Myers Squibb International Corporation400
进行中（未招募）
不适用
A randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors.Revised protocol 01 incorporating Amendment 02 + Pharmacogenetics Blood Sample Amendment 01 (version 1.0, dated 28-Jan-2008)Subjects with Advanced Solid TumorsMedDRA version: 9.1Level: LLTClassification code 10065252Term: Solid tumorEUCTR2008-000087-16-NLBristol Myers Squibb International Corporation400
进行中（未招募）
1 期
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor TypesEUCTR2008-000087-16-BEBristol-Myers Squibb International Corporation400
进行中（未招募）
1 期
A randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors.Revised protocol 01 incorporating Amendment 02Subjects with Advanced Solid TumorsMedDRA version: 9.1Level: LLTClassification code 10065252Term: Solid tumorEUCTR2008-000087-16-FRBristol Myers Squibb International Corporation400